MARATTO

article · Neuro-Oncology Advances

LGGL-01 “INTERVENTION OUTCOMES OF ENHANCED RECOVERY AFTER SURGERY PROTOCOL VERSUS STANDARD CARE FOR GLIOMA PATIENTS IN SELECTED HOSPITALS IN DEMOCRATIC REPUBLIC OF THE CONGO: RANDOMIZATION AND STRATIFICATION OF PROVIDERS AND HOSPITALS”

Abstract

Abstract Enhanced Recovery after Surgery (ERAS) protocols aim to improve perioperative care and patient outcomes. A pragmatic, multicenter, randomized controlled trial will be conducted in the Democratic Republic of Congo (DRC) to assess ERAS’ efficacy compared to the current standard of care (SOC) for glioma patients. Eligible providers will be randomized at the surgical team level to ERAS or SOC, ensuring consistent practices within teams. Hospitals representing diverse healthcare settings will be included, and randomization will be stratified by hospital to ensure balance. 100 glioma patients (50 in each group) will be included, and primary analysis expects fewer post-operative complications and shorter hospital stays in the ERAS group, with higher patient satisfaction. Subgroup analyses will be conducted by hospital center. Randomization and stratification aim to mitigate provider and hospital-specific influences, enhancing the study’s validity and equitable representation. This unique trial design seeks to provide insights into ERAS benefits for glioma patients in resource-constrained settings, guiding clinical practice and healthcare policy to improve care and outcomes.

Research topics

  • Cardiac, Anesthesia and Surgical Outcomes

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1093/noajnl/vdae147.004

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.